Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy‐induced amenorrhea

Publisher： John Wiley & Sons Inc

E-ISSN： 1542-4863|68|1|5-6

ISSN： 0007-9235

Source： CA: A CANCER JOURNAL FOR CLINICIANS, Vol.68, Iss.1, 2018-01, pp. : 5-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adjuvant Aromatase Inhibitor Therapy in Patients with Stage I Breast Cancer at a Regional Oncology Center in Israel: Implementation of a ‘Switching' Policy in Postmenopausal Patients after Initial Tamoxifen

By  

Oncology, Vol. 85, Iss. 3, 2013-08 ,pp. : 145-152

Karger

Access to resources Recommend Favorite

Effect of Adjuvant Tamoxifen Therapy on Thyroid Function in Postmenopausal Women with Breast Cancer

By  

Oncology, Vol. 56, Iss. 1, 1999-01 ,pp. : 43-45

Karger

Access to resources Recommend Favorite

Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data

By Ellis Matthew J.   Rigden Caron E.  

Current Medical Research and Opinion, Vol. 22, Iss. 12, 2006-12 ,pp. : 2479-2487

Informa Healthcare

Access to resources Recommend Favorite

Patient‐reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy

By  

CANCER, Vol. 120, Iss. 16, 2014-08 ,pp. : 2403-2411

John Wiley & Sons Inc

Access to resources Recommend Favorite

Eligibility, Compliance and Persistence of Sequential Therapy with Aromatase Inhibitors following 2–3 Years of Tamoxifen in Endocrine Adjuvant Breast Cancer Therapy

By  

Oncology, Vol. 81, Iss. 3-4, 2011-10 ,pp. : 151-157

Karger

Access to resources Recommend Favorite